LSL Pharma Group Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '21 Jul 31, 2021
Cash & Equivalents	0.55	0.3	0.01	0.01	-
Cash & Short-Term Investments	0.55	0.3	0.01	0.01	-
Cash Growth	85.14%	3600.00%	-	-	-
Accounts Receivable	5.5	4.95	2.68	1.23	-
Other Receivables	-	-	-	-	0.02
Total Trade Receivables	5.5	4.95	2.68	1.23	0.02
Inventory	12.35	9.22	4.11	2.96	-
Other Current Assets	5.7	1.02	0.41	0.21	-
Total Current Assets	24.1	15.48	7.2	4.4	0.02
Net Property, Plant & Equipment	32.77	22.94	14.75	13.92	-
Other Intangible Assets	17.47	13.27	8.93	8.98	-
Goodwill	0.16	0.16	-	-	-
Other Long-Term Assets	0.24	1.77	0.02	0.02	-
Total Assets	74.74	53.61	30.9	27.31	0.02
Accounts Payable	6.23	5.3	5.98	6.12	0.09
Short-Term Debt	2.53	2.56	3.77	3.78	0.11
Current Portion of Long-Term Debt	0.87	1.45	5.22	1.58	-
Current Portion of Leases	0.69	0.45	0.12	0.14	-
Unearned Revenue	-	-	-	0.01	-
Total Current Liabilities	10.31	9.75	15.07	11.62	0.2
Long-Term Debt	26.66	12.75	4.73	7.84	-
Long-Term Leases	7.61	4.66	2.44	2.56	-
Other Long-Term Liabilities	3.19	1.79	-	-	-
Total Long-Term Liabilities	37.46	19.2	7.17	10.4	-
Total Liabilities	47.77	28.72	22.25	22.02	0.2
Common Stock	40.47	36.39	24.2	15.05	2.93
Additional Paid-in Capital	4.24	3.42	2.69	-	0.45
Retained Earnings	-17.74	-14.92	-18.23	-9.76	-3.56
Shareholders' Equity	26.97	24.89	8.66	5.29	-0.19
Total Liabilities & Equity	74.74	53.61	30.9	27.31	17.31
Total Debt	38.35	21.87	16.27	15.9	0.11
Net Cash (Debt)	-37.8	-21.57	-16.26	-15.89	-0.11
Net Cash Per Share	-0.32	-0.20	-0.20	-0.24	-0.01
Book Value	26.97	24.89	8.66	5.29	-0.19
Book Value Per Share	0.23	0.24	0.11	0.08	-0.01
Tangible Book Value	9.34	11.46	-0.28	-3.69	-0.19
Tangible Book Value Per Share	0.08	0.11	-0.00	-0.05	-0.01

Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.